What Is Semax? Where It Came From, and When
The definition is short. The sequence of events behind it explains why this compound looks legitimate from one angle and completely unregulated from another.
The short answer to what is Semax: a synthetic peptide derived from a fragment of ACTH, developed in Russia and used medically inside that country. The longer answer is a sequence of events, and the order they happened in is what explains the strange position the compound occupies today.
Where the order actually gets placed
Ascension Peptides, Semax
US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.
The published certificate for batch 30-05260628 carries a kinetic chromogenic LAL endotoxin test to USP Chapter 85, reporting under 0.20 EU/mL against a 0.5 EU/mL limit, plus a sterility screen. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price.
- Two batch certificates per lot
- Shipping free over $250
- Out the door same day if you order before 2pm CST
Everything here is research material for laboratory use, not for human consumption. Affiliate links, so we may earn a commission at no cost to you. Prices last checked August 21, 2026.
Answering what is Semax in the order the answer was assembled
Most definitions of a compound are written as if identity were a fixed property. Here it is not. This peptide's identity is the output of a chain: a molecule was designed, work was done on it in one country, it entered medical use there, it acquired a regulatory position there, and then it crossed a border where none of that followed it. Each link changes the meaning of the one before.
Take the chain apart and the confusion in most consumer descriptions resolves. The pages that call it an approved Russian medicine and the pages that call it an unregulated grey market chemical are describing different links, and both are describing something real.
The starting material, and what a fragment does not inherit
ACTH is a hormone. This peptide is a synthetic construct derived from a fragment of it.
Being derived from a fragment of a hormone does not make something a hormone. A fragment is a different molecule with a different shape, different stability and different binding behaviour, and it does not carry the parent's activity by inheritance. Readers who see the hormone name and reason forward to hormonal effects are making an inference the chemistry does not license, in either direction.
What the origin does explain is why anyone looked. Interest in the nervous system followed from where the starting material came from, so the parent hormone set the research question. It did not answer it. That distinction survives all the way through the rest of this page.
The stage that happened inside one country
Development, laboratory work, clinical study and medical use all took place in Russia. That record exists. It includes clinical work and a regulatory position, and dismissing it as invented is simply wrong.
Here is the part that gets skipped. A reader outside Russia usually cannot inspect it. Language is the first barrier, journal indexing is the second, and access to a national regulator's review file is the third. So a person cannot check which indications it is authorised for, what evidence the reviewers saw, how the studies were designed, who was enrolled, or what adverse events were recorded and how they were classified.
That produces two opposite errors, and this site sees both constantly. The first is to say the evidence does not exist. It does. The second is to treat it as interchangeable with a Western registration file. That is a claim about the contents of a document nobody making the claim has read. A registration dossier is not a badge, it is a specific body of evidence assessed against a specific standard, and asserting equivalence without access to either is not a conclusion, it is a hope.
The stage that never happened anywhere else
Outside Russia the chain stops.
There are no registered interventional trials for this compound on ClinicalTrials.gov, which is why this page carries no trial identifier: there is no legitimate one to give. There is no FDA, EMA or MHRA authorisation. Nothing is pending that a member of the public could look up and follow.
It is worth being precise about why, because the usual assumption is wrong. No Western regulator examined this peptide and rejected it. No one submitted it. A registration programme needs a sponsor willing to fund years of trials, and a sponsor needs a commercial reason, which usually means exclusivity on a molecule that has been public for decades. The absence here is an absence of applicants, not a verdict.
That leaves a compound with a real clinical history in one jurisdiction and no regulatory standing in any other, which is exactly the gap that vendors sell into.
The stage where it becomes a product, in two different containers
This is the link that matters most in practice, and it is where the sequence stops being historical and starts being something happening in your hallway.
Material sold in English speaking markets arrives in one of two formats, and they are not the same experience.
A nasal spray arrives as a pre-mixed solution in a pump bottle. Nothing needs preparing. The concentration is whatever the seller printed, the volume per actuation is whatever that pump was built to deliver, and the person using it has no way to confirm either figure. The format is the problem: a spray bottle looks like a pharmacy product, and looking like one invites being treated like one.
A vial arrives as dry powder and has to be reconstituted before anything happens at all. That extra step turns the buyer into the person preparing the preparation, in a kitchen, with no sterility assurance and no analysis.
Both formats share the underlying issue. The label is a claim made by the seller about material the seller sourced. A certificate of analysis, when one is offered, documents a batch at a moment, not the specific unit in your hand, and it is supplied by the party with an interest in the result. The Russian medical product and a research chemical carrying the same molecule name are not the same object, and no amount of shared nomenclature makes them one.
| Stage in the chain | What happened | Where it holds | What a reader elsewhere can verify |
|---|---|---|---|
| Molecular origin | Derived from a fragment of ACTH | Chemistry, everywhere | The description, not the consequences |
| Laboratory work | Cell culture and rodent studies | Published, largely in Russian | Partly, and only through translation |
| Clinical use | Real, and ongoing in that country | Russia | Not directly |
| Regulatory position | A national authorisation | Russia, for a specific product | No, the review file is not open to you |
| Western registration | Did not happen, was never applied for | Nowhere | Yes, the absence is checkable |
| Retail supply | Nasal spray or vial, sold as a research chemical | Online | Only the seller's own statements |
What the word approved is doing at each point
Approval is not a property of a molecule. It is a decision about a product, made by one authority, for defined uses, on the basis of a file.
So the sentence "it is approved in Russia" is true and narrow at the same time. It is about a manufactured product made under an inspected process, with contents that were characterised, sold with labelling that a regulator reviewed, for indications that regulator accepted. Every one of those conditions is a property of that product in that system. None of them attaches to a powder shipped from a website in a different country.
That is the transfer failure at the centre of this compound. It is not that the Russian record is weak. It is that approval does not travel, and neither does the manufacturing, the labelling, the indication or the oversight that made the approval mean anything.